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Abstract In an attempt to elucidate signal transduction path-
ways which may modulate DNA binding of the transcription
factor c-Myb, we investigated whether c-Myb could be a target
for the signaling molecule nitric oxide (NO) in vitro. NO-
generating agents severely inhibited specific DNA binding of the
c-Myb minimal DNA-binding domain R2R3. This inhibition was
readily reversible upon treatment with excess DTT. A redox-
sensitive cysteine (C130) was required for this NO sensitivity.
Moreover, a DNA-binding domain carrying two of the avian
myeloblastosis virus (AMV)-specific mutations (L106H, V117D)
appeared to be less sensitive to S-nitrosylation than the wild-type
c-Myb. This difference in NO sensitivity may influence the
regulation of wild type versus AMV v-Myb protein function.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The activity of many transcription factors is regulated by
signal transduction-dependent mechanisms, ranging from the
regulation of transport into the nucleus to modi¢cations that
modulate DNA binding or interaction with other proteins,
which result in altered transactivation of target genes [1].
Modi¢cation and regulation by phosphorylation is well estab-
lished, and has been studied in detail for several transcription
factors. More recently, ayyention has also been focused on the
regulation of transcription factors by redox mechanisms and
nitric oxide. Nitric oxide (NO) is involved in a wide range of
biological processes, including blood vessel and macrophage
function, neurotransmission, growth control and regulation of
transcription (reviewed in [2^5]). NO exerts its e¡ect on down-
stream protein targets either by generating S-nitroso modi¢-
cations of speci¢c protein thiols or by reacting with metal-
containing proteins [2]. Nitric oxide bound to proteins (e.g.
albumin in plasma) or to peptides (e.g. glutathione in cells)
serves to prolong the biological activity of nitric oxide by
acting as a slow-releasing reservoir [3,6]. In Escherichia coli,
the transcriptional activity of OxyR (inducer of hydroperoxi-
dase I) is activated by S-nitrosylation [7], whereas the SoxR
transcription factor (an activator of antioxidant genes) is ac-
tivated by NO reacting with an iron-sulfur cluster [8]. In high-
er eukaryotes, central signal-responsive transcription factors
such as NF-UB and AP-1 have been reported to be stimulated
or inhibited by NO depending on the cell system and signaling
pathway [9^15].
The c-myb proto-oncogene has been extensively character-
ized (reviewed in [16,17]), but little information is available
regarding regulation of c-Myb function by signal transduction
mechanisms. One report has shown that CK2 phosphoryla-
tion of serines 11 and 12 inhibits speci¢c DNA binding,
whereas MAPK-dependent phosphorylation of serine 532 in
the negative regulatory domain increased c-Myb’s transcrip-
tional capacity on some promoters (see references in [17]). The
c-Myb DNA-binding domain consists of three tryptophan-
rich repeats, R1, R2 and R3. A highly conserved cysteine
residue (C130) is located in a £exible region of the R2 repeat,
and thought to line a cavity in the structure [18,19]. This
residue is essential for DNA binding, transformation and
transcriptional transactivation [20,21]. The strong conserva-
tion of this cysteine cannot be explained simply by being
required for DNA binding, as several hydrophobic replace-
ments did not weaken the sequence-speci¢c DNA-binding ac-
tivity compared to the wild type protein [22]. This cysteine
residue is also highly redox-sensitive. We have previously pro-
posed a model where the C130 residue may function as a
redox-sensitive molecular switch, which by induction of a con-
formational change in the R2 repeat a¡ects speci¢c DNA
binding of c-Myb [22]. Regulation of transcription factor
DNA binding by redox modi¢cation of cysteines has been
reported for an increasing number of transcription factors,
including AP-1, Sp-1, NF-UB and p53 [23]. Cysteine residues
in both AP-1 and NF-UB are targeted by both redox and NO-
generating agents/pathways. We therefore tested whether c-
Myb could be a target for S-nitrosylation and whether this
modi¢cation could alter the DNA-binding activity of the pro-
tein.
In this report we show that the NO donors SNP (sodium
nitroprusside) and SNOG (S-nitrosoglutathione) severely re-
duce the DNA-binding activity of c-Myb and that the C130
residue is required for this inhibitory e¡ect. S-Nitrosylated
c-Myb could be readily reactivated by treatment with an
excess of dithiothreitol (DTT). We also found that the
DNA-binding domain of avian myeloblastosis virus (AMV)
v-Myb was less sensitive towards S-nitrosylation than the wild
type, and thereby possessed signi¢cant DNA-binding activity
under conditions where the wild type protein was severely
inhibited.
2. Materials and methods
2.1. Expression and puri¢cation of Myb proteins
The minimal DNA-binding domain of chicken c-Myb, R2R3, and
mutant derivatives R2R3[C130V] and R2R3[AMV] (mutations L106H
and V117D in R2, described in [24]) were expressed in E. coli using the
T7 system [25]. Recombinant proteins were puri¢ed as described pre-
viously [26] and diluted in HGE500 (20 mM HEPES, 1 mM EDTA,
10% v/v glycerol, 500 mM NaCl, 0.05% v/v Triton X-100, pH 8.0).
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2.2. Electrophoretic mobility shift assay
DNA binding was monitored by electrophoretic mobility shift assay
(EMSA) [24] using the double-stranded oligonucleotide probe (5P-
GCATTATAACGGTTTTTTAGCGC-3P) (mim-1 site A) [17]. SNP,
glutathione (GSH) (both from Sigma), and SNOG (Calbiochem) were
made fresh from powder dissolved in N2-£ushed MilliQ-puri¢ed dis-
tilled water.
All binding reactions were performed in an oxygen-free atmosphere
(N2 gas) with 20 fmol protein in a total volume of 15 Wl in 24 mM
HEPES, 0.3 mM EDTA, 100 mM NaCl, 12% v/v glycerol, pH 8.0.
Samples treated with SNP and/or with DTT were incubated at 25‡C
for 5 min. Samples treated with SNOG or with GSH were incubated
for 30 min at 25‡C. After treatments, 5P-32P-labelled DNA oligo probe
(10 fmol) was added and the binding mixture incubated for an addi-
tional 2 min at 25‡C before electrophoresis.
For investigation of the stability of nitrosylated c-Myb R2R3[wt] in
normal atmosphere, the samples were prepared as follows: R2R3[wt]
protein (400 fmol) was treated with 1 mM DTT and with or without
6 mM SNP in TE bu¡er (10 mM Tris-HCl, 1 mM EDTA, pH 8.0)
containing 0.1 mg/ml BSA for 5 min at 25‡C in an oxygen-free at-
mosphere. Excess SNP was removed by centrifugation through a Se-
phacryl S-200 HR gel ¢ltration column (Pharmacia Biotech) equili-
brated in TE bu¡er. The eluate was incubated in normal atmosphere
at 25‡C. Aliquots were removed at various timepoints and added to
the binding bu¡er in a total volume of 15 Wl (¢nal conditions as
above) containing 10 fmol probe. Binding reactions were incubated
for 2 min at 25‡C before immediate loading on the running EMSA
gel.
3. Results
3.1. Inactivation of c-Myb R2R3 [wt] DNA binding by the
NO donors SNP and SNOG
We ¢rst investigated the e¡ects of NO-generating agents on
the DNA-binding activity of chicken c-Myb wild type mini-
mal DNA-binding domain R2R3[wt]. Recombinant c-Myb
R2R3[wt] was incubated with the NO donor SNP in an oxy-
gen-free atmosphere in the presence or absence of DTT before
analysis by EMSA. The DNA-binding activity of R2R3[wt]
was greatly reduced by treatment with SNP (Fig. 1, lanes 1^
3).
We have previously shown that the cysteine residue C130 in
the R2 subdomain is readily oxidized, and that oxidation of
this residue disrupts DNA binding of the R2R3[wt] protein
[22]. Since cysteines are potential targets for S-nitrosylation
[2], we tested whether the C130 residue of c-Myb was involved
in the NO-mediated inhibitory e¡ects. The R2R3[C130V] mu-
tant protein, where cysteine-130 is replaced by valine, was
similarly treated with SNP and DTT. EMSA analysis showed
only a slight reduction in the DNA binding of the C130V
mutant protein (Fig. 1, lanes 4^6). In other experiments,
this reduction was hardly apparent (see Fig. 4, lanes 13 and
14). Accordingly, the C130 residue must be the target for the
major SNP e¡ect. The latter result also excludes the possibil-
ity that SNP or SNP-derived products act independently of
cysteine modi¢cation and mediate signi¢cant inhibition of c-
Myb R2R3[wt] DNA-binding activity.
Treatment with SNP and DTT together inhibited DNA
binding of R2R3[wt] to a greater extent than SNP alone
(Fig. 1, lanes 2 and 3). This e¡ect was not due to inhibition
of DNA binding by DTT itself. Previous reports have shown
that DTT stimulated DNA-binding activity of oxidized c-Myb
R2R3[wt] [20,24]. Furthermore, the enhanced negative e¡ect
of DTT on DNA binding was not observed with the [C130V]
mutant (lanes 4 and 6). Tabuchi and colleagues also noted the
apparent DTT enhancement of the SNP e¡ects on AP-1 DNA
binding, and suggested that this may be due to the formation
of S-nitroso-DTT which subsequently reacts with the target
protein [14].
To con¢rm and extend these ¢ndings, we tested the more
physiological NO donor SNOG. C-Myb R2R3[wt] and
[C130V] mutant proteins were incubated with increasing
amounts of SNOG followed by EMSA analysis of DNA-
binding activity. As shown in Fig. 2, treatment with increasing
concentrations of SNOG rapidly abolished c-Myb R2R3[wt]
DNA-binding activity (lanes 1^5) whereas the c-Myb
R2R3[C130V] mutant was una¡ected (lanes 7^11), again dem-
onstrating the speci¢city of the nitrosylation. Treatment with
glutathione alone (lanes 6 and 12) had no such e¡ect on either
wild type or mutant protein, which excluded the glutathione
moiety as an inhibitor of DNA binding. The NO donor
SNOG was much more e⁄cient at inhibiting DNA binding
than SNP.
3.2. The stability of S-nitrosylated c-Myb R2R3[wt] and
reactivation of the protein by DTT
NO radicals released from NO donors such as SNP are
short-lived reactive molecules with a half-life in the order of
seconds depending on the concentration [27]. Compounds
such as S-nitroso proteins have a much longer life-time. The
half-life of S-nitroso-BSA is V24 h in phosphate bu¡er (pH
7.4; 25‡C) and V40 min in plasma [28]. Data suggest that
particularly thiol nitrosylation serves to prolong the biological
activity of nitric oxide by acting as a slow-releasing reservoir
[28,29]. A regulatory role for nitrosylation of c-Myb would
necessitate the modi¢cation being readily reversible and su⁄-
ciently stable for e¡ects on downstream targets. We therefore
investigated the stability of S-nitrosylated c-Myb R2R3[wt] in
a normal aerobic atmosphere, and whether the S-nitrosylation
of C130 was reversible.
Puri¢ed c-Myb R2R3[wt] was treated with SNP in the pres-
ence of DTT in an oxygen-free atmosphere and centrifuged
through a gel ¢ltration column to remove excess SNP. The
column eluate was then exposed to air at 25‡C for up to
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Fig. 1. Inhibition of the DNA-binding activity of the c-Myb
R2R3[wt] protein by the NO donor SNP. Wild type and mutant
forms of the minimal DNA-binding domain of c-Myb, R2R3, were
expressed in E. coli and puri¢ed to near homogeneity. The e¡ect of
NO on DNA binding was analyzed as follows: wild type c-Myb
R2R3[wt] (lanes 1^3) and mutant R2R3 [C130V] (lanes 4^6) proteins
(20 fmol) were treated without (3) or with 5 mM SNP (+) in the
presence (+) or absence (3) of 1 mM DTT for 5 min before bind-
ing to a mim-1 A site oligo probe. The protein-DNA complexes
were analyzed by electrophoretic mobility shift assay (EMSA) as de-
scribed in Section 2. Positions of protein-DNA complexes and free
probe are indicated.
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20 min before initiating the DNA-binding reaction. As shown
in Fig. 3, there was no reactivation of DNA binding of c-Myb
R2R3[wt] during this 20 min incubation period (lanes 2^7). In
contrast, addition of excess DTT to the binding bu¡er (lane 1)
readily reactivated DNA binding. Control EMSA reactions
with c-Myb R2R3[wt] protein treated as above except for
SNP demonstrated that active protein was eluted in a high
yield from the column and was not inactivated by the column
matrix, nor by incubation under aerobic conditions (lanes 8^
10). We conclude that S-nitrosylated c-Myb R2R3[wt] is stable
for at least 20 min in normal atmosphere, and that the S-
nitrosylation is readily reversible.
3.3. The AMV-speci¢c mutations in R2 alter the sensitivity of
the DNA-binding domain towards S-nitrosylation
The oncogenic AMV version of c-Myb carries three amino
acid substitutions in the R2 subdomain. Two mutations have
been mapped by transformation assays to be essential for the
AMV-transformed phenotype [16]. We have recently shown
that a mutant protein carrying these two mutations (L106H,
V117D) exhibits a more compact conformation in R2 and
reduced sensitivity towards cysteine-speci¢c alkylation and ox-
idation [24]. We asked whether these two AMV-speci¢c mu-
tations also could in£uence nitrosylation of the C130 residue.
C-Myb R2R3[wt] and R2R3[AMV] recombinant proteins were
treated with increasing concentrations of SNP in the presence
of DTT and analyzed by EMSA. As shown in Fig. 4, the
R2R3[AMV] protein (lanes 7^12) was more resistant than
R2R3[wt] (lanes 1^6) to SNP-induced loss of DNA-binding
activity. The R2R3[C130V] mutant was una¡ected by the
SNP treatment (lanes 13 and 14), demonstrating the cysteine
speci¢city of the nitrosylation. This experiment shows that the
AMV-speci¢c mutations in R2 render the protein less sensitive
towards nitrosylation, possibly as a result of a more compact
structure induced by the point mutations in R2.
4. Discussion
We have presented data showing that the second messenger
molecule NO is able to disrupt the speci¢c DNA-binding ac-
tivity of the transcription factor c-Myb by interaction with a
speci¢c cysteine residue (C130) located in the R2 repeat of the
DNA-binding domain. This inhibitory e¡ect is fully reversible
by treatment with excess DTT.
We have previously shown that when the C130 residue in c-
Myb is oxidized, alkylated or mutated to a polar residue, the
protein adopts a more open structure and has a severely im-
paired speci¢c DNA-binding activity [22] (note that C130 was
designated C43 in this reference). The critical importance of
the size and polarity of the residue at this position may be
explained by the cysteine lining a hydrophobic cavity in the
R2 domain [19]. This cavity may confer the necessary degree
of £exibility needed for speci¢c DNA interaction. The basic
region encompassing the C130 residue resembles the basic
DNA-binding motif (containing a highly conserved redox-sen-
sitive cysteine residue) of the Fos/Jun and other leucine zipper
family transcription factors [30]. As pointed out recently by
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Fig. 3. Stability of nitrosylated c-Myb R2R3[wt] protein in normal
atmosphere. Puri¢ed c-Myb R2R3[wt] (400 fmol) was treated with
1 mM DTT and with or without 6 mM SNP in an oxygen-free at-
mosphere before removal of excess SNP by centrifugation through a
gel ¢ltration column (described in Section 2). Column eluates were
incubated in normal atmosphere at 25‡C. Aliquots from SNP-
treated protein were removed at 0, 2, 5, 10, 15 and 20 min (lanes
2^7). Aliquots from protein treated identically, but omitting SNP,
were removed after 0 and 20 min (lanes 9, 10) and added to the
binding reactions. Lane 1: 50 mM DTT was included in the binding
reaction. Lane 8: precolumn aliquot of protein treated without
SNP. The complexes were analyzed as previously described. The dif-
ference in migration of the protein-DNA complexes and free probe
is due to samples being loaded on a running gel. Positions of pro-
tein/DNA complexes and free probe are indicated.
Fig. 2. Inhibition of the DNA-binding activity of the c-Myb R2R3[wt] protein by the NO donor SNOG. Puri¢ed c-Myb R2R3[wt] or
R2R3[C130V] proteins (20 fmol) were treated with 0, 0.1, 0.5, 1.0 or 2.5 mM SNOG (lanes 1^5 and 7^11, respectively) or with 2.5 mM GSH
alone (lanes 6 and 12) for 30 min before binding to the oligo probe and EMSA analysis. Positions of protein-DNA complexes and free probe
are indicated.
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Stamler et al. [4], relevant cysteine targets for S-nitrosylation
seem to be located close to basic and acidic residues probably
because such residues allow base-catalyzed nitrosylation and
acid-catalyzed denitrosylation. The c-Myb C130 seems to ¢t
this requirement since it is located in a stretch of six residues
of which three are basic and one acidic. Taken together, these
particular structural features make C130 a very sensitive tar-
get for modi¢cation. We predict that S-nitrosylation disrupts
DNA binding by a structural e¡ect similar to the one previ-
ously proposed for redox modi¢cation of C130 in c-Myb [22].
Nitric oxide mediates inhibition of DNA binding of NF-UB
both in vivo and in vitro [9^12]. The p50 cysteine-62 residue in
the DNA-binding domain is speci¢cally S-nitrosylated, which
leads to a four-fold reduction in DNA-binding activity. The
DNA-binding activity of AP-1 is also inhibited both in vitro
and in vivo [14,15]. A highly conserved cysteine in the basic
DNA-binding domain is the target of S-nitrosylation, but the
exact molecular mechanism for inhibition of DNA binding
has not yet been determined. We speculate that a common
theme for c-Myb, NF-UB and AP-1 may be the targeting of
speci¢c cysteine residues by NO signaling pathways, and loss
of DNA-binding activity by S-nitrosylation-induced confor-
mational changes in the DNA-binding domains.
This biochemical study has not addressed directly the ques-
tion of whether S-nitrosylation plays a role in the regulation
of c-Myb activity in vivo. In general, the intracellular environ-
ment is strongly reducing, with intracellular concentrations of
GSH and GSSG of approximately 10 mM and 0.5 mM, re-
spectively [31]. One would therefore expect regulatory mech-
anisms to be highly speci¢c and readily reversible. One re-
quirement would be that c-Myb is su⁄ciently sensitive
towards S-nitrosylation at physiological concentrations of
NO. Free NO in the brain is in the range 10 nM^2 WM,
although this would be expected to vary with cell type and
intracellular conditions [32]. The concentration of free NO in
EMSA binding bu¡er containing 1^5 mM SNP has been
measured to be in the range 20^100 nM [11], well within
physiologically relevant concentrations of NO. The DNA
binding of c-Myb was strongly inhibited by 5 mM SNP and
0.5 mM SNOG.
Nitric oxide has been reported to act as an antiproliferative
agent, both during Drosophila development [33] and in neuro-
nal cells after NGF stimulation [5]. Expression of c-Myb, on
the other hand, has been tightly associated with stimulation of
proliferation. A crucial role for c-Myb in hematopoiesis seems
to be to maintain the proliferative state of immature cells
(reviewed in [16,17]). Likewise, antisense oligonucleotides di-
rected against c-myb have antiproliferative e¡ects [17]. The
targets for the antiproliferative e¡ects of NO have yet to be
identi¢ed. Based on our results presented in this paper, we
suggest that c-Myb may be one such target for NO action.
We have previously shown that the introduction of two
AMV mutations (L106H, V117D) into the c-Myb minimal
DNA-binding domain resulted in less stable protein-DNA
complexes in vitro, and reduced transactivation in vivo com-
pared to the wild type protein [24]. In the present work we
found that an AMV v-Myb DNA-binding domain with the
L106H and V117D mutations was less sensitive towards S-
nitrosylation than the wild type protein. These are intriguing
properties for a product of a potent nuclear oncogene. One
possibility may be that oncogenic AMV v-Myb may be active
in the cell under circumstances where normal c-Myb should
be inactive. A better understanding of NO signaling in c-Myb
expressing cells will be required to ¢nally evaluate the impor-
tance of the reduced NO and redox sensitivity in v-Myb
caused by the AMV-speci¢c point mutations.
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